Cayman Latanoprostene Bunod Cayman Latanoprostene Bunod

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Patents for Nicox\u2019s Latanoprostene Bunod, Commercialized as VYZULTA\u00ae, Eligible for Patent Term Extension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Licensee Bausch + Lomb Launches VYZULTA (Latanoprostene Bunod Ophthalmic Solution), 0.024% in Taiwan and Receives Approval in Qatar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Licensee Bausch + Lomb Receives Approval for VYZULTA\u00ae (latanoprostene bunod ophthalmic solution), 0.024% in UAE","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Announces VYZULTA\u00ae (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in Brazil","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Announces Additional Expanded Public Coverage for (Pr)VYZULTA\u00ae (Latanoprostene Bunod Ophthalmic Solution 0.024% w\/w) in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Licensee Bausch + Lomb Secures Approval of VYZULTA\u00ae in Colombia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Announces Vyzulta\u00ae (latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved in South Korea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Latanoprostene Bunod

    Menu

    Latanoprostene Bunod

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nicox SA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries

              Details:

              Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

              Lead Product(s): Latanoprostene Bunod

              Therapeutic Area: Ophthalmology Product Name: Vyzulta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bausch & Lomb Incorporated

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nicox SA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in UAE

              Details:

              Under the terms of the exclusive global license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestone payments.

              Lead Product(s): Latanoprostene Bunod

              Therapeutic Area: Ophthalmology Product Name: Vyzulta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bausch & Lomb Incorporated

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nicox’s Licensee Bausch + Lomb Launches VYZULTA (Latanoprostene Bunod Ophthalmic Solution), 0.024% in Taiwan and Receives Approval in Qatar

              Details:

              VYZULTA® (latanoprostene bunod ophthalmic solution), is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.

              Lead Product(s): Latanoprostene Bunod

              Therapeutic Area: Ophthalmology Product Name: Vyzulta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nicox SA

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension

              Details:

              VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.

              Lead Product(s): Latanoprostene Bunod

              Therapeutic Area: Ophthalmology Product Name: Vyzulta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bausch & Lomb Incorporated

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in Brazil

              Details:

              Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

              Lead Product(s): Latanoprostene Bunod

              Therapeutic Area: Ophthalmology Product Name: Vyzulta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nicox SA

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bausch & Lomb Incorporated

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bausch Health Announces Vyzulta® (latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved in South Korea

              Details:

              Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

              Lead Product(s): Latanoprostene Bunod

              Therapeutic Area: Ophthalmology Product Name: Vyzulta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nicox SA

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bausch & Lomb Incorporated

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nicox’s Licensee Bausch + Lomb Secures Approval of VYZULTA® in Colombia

              Details:

              Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

              Lead Product(s): Latanoprostene Bunod

              Therapeutic Area: Ophthalmology Product Name: Vyzulta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nicox SA

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bausch & Lomb Incorporated

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bausch + Lomb Announces Additional Expanded Public Coverage for (Pr)VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024% w/w) in Canada

              Details:

              Vyzulta (latanoprostene bunod) is a prostaglandin analog, which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

              Lead Product(s): Latanoprostene Bunod

              Therapeutic Area: Ophthalmology Product Name: Vyzulta

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nicox SA

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Gentec SA Latanoprostene Bunod
              Chirogate Latanoprostene Bunod RMB
              Close
              4
              Post Enquiry
              POST ENQUIRY